319 related articles for article (PubMed ID: 27126081)
21. Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
Zakaria Z; Tivnan A; Flanagan L; Murray DW; Salvucci M; Stringer BW; Day BW; Boyd AW; Kögel D; Rehm M; O'Brien DF; Byrne AT; Prehn JH
Br J Cancer; 2016 Jan; 114(2):188-98. PubMed ID: 26657652
[TBL] [Abstract][Full Text] [Related]
22. ER stress in temozolomide-treated glioblastomas interferes with DNA repair and induces apoptosis.
Weatherbee JL; Kraus JL; Ross AH
Oncotarget; 2016 Jul; 7(28):43820-43834. PubMed ID: 27286262
[TBL] [Abstract][Full Text] [Related]
23. Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells.
Hui AM; Zhang W; Chen W; Xi D; Purow B; Friedman GC; Fine HA
Cancer Res; 2004 Dec; 64(24):9115-23. PubMed ID: 15604281
[TBL] [Abstract][Full Text] [Related]
24. Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide.
Murphy SF; Varghese RT; Lamouille S; Guo S; Pridham KJ; Kanabur P; Osimani AM; Sharma S; Jourdan J; Rodgers CM; Simonds GR; Gourdie RG; Sheng Z
Cancer Res; 2016 Jan; 76(1):139-49. PubMed ID: 26542214
[TBL] [Abstract][Full Text] [Related]
25. Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas.
Kratzsch T; Kuhn SA; Joedicke A; Hanisch UK; Vajkoczy P; Hoffmann J; Fichtner I
J Cancer Res Clin Oncol; 2018 May; 144(5):809-819. PubMed ID: 29427211
[TBL] [Abstract][Full Text] [Related]
26. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M
Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558
[TBL] [Abstract][Full Text] [Related]
27. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Berenguer-Daizé C; Astorgues-Xerri L; Odore E; Cayol M; Cvitkovic E; Noel K; Bekradda M; MacKenzie S; Rezai K; Lokiec F; Riveiro ME; Ouafik L
Int J Cancer; 2016 Nov; 139(9):2047-55. PubMed ID: 27388964
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma.
Pratap UP; Sareddy GR; Liu Z; Venkata PP; Liu J; Tang W; Altwegg KA; Ebrahimi B; Li X; Tekmal RR; Viswanadhapalli S; McHardy S; Brenner AJ; Vadlamudi RK
Neurooncol Adv; 2021; 3(1):vdab099. PubMed ID: 34485908
[TBL] [Abstract][Full Text] [Related]
29. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
[TBL] [Abstract][Full Text] [Related]
30. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
[TBL] [Abstract][Full Text] [Related]
31. A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation.
Chen X; Tai L; Gao J; Qian J; Zhang M; Li B; Xie C; Lu L; Lu W; Lu W
J Control Release; 2015 Nov; 218():29-35. PubMed ID: 26428461
[TBL] [Abstract][Full Text] [Related]
32. Anticancer activity of osmium(VI) nitrido complexes in patient-derived glioblastoma initiating cells and in vivo mouse models.
Berger G; Grauwet K; Zhang H; Hussey AM; Nowicki MO; Wang DI; Chiocca EA; Lawler SE; Lippard SJ
Cancer Lett; 2018 Mar; 416():138-148. PubMed ID: 29246647
[TBL] [Abstract][Full Text] [Related]
33. Low-Dose DMC Significantly Enhances the Effect of TMZ on Glioma Cells by Targeting Multiple Signaling Pathways Both In Vivo and In Vitro.
Shi L; Sun G
Neuromolecular Med; 2015 Dec; 17(4):431-42. PubMed ID: 26458914
[TBL] [Abstract][Full Text] [Related]
34. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
[TBL] [Abstract][Full Text] [Related]
35. Preclinical Development of Brain Permeable ERβ Agonist for the Treatment of Glioblastoma.
Pratap UP; Tidwell M; Balinda HU; Clanton NA; Yang X; Viswanadhapalli S; Sareddy GR; Liang D; Xie H; Chen Y; Lai Z; Tekmal RR; McHardy SF; Brenner AJ; Vadlamudi RK
Mol Cancer Ther; 2023 Nov; 22(11):1248-1260. PubMed ID: 37493258
[TBL] [Abstract][Full Text] [Related]
36. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
37. Antitumor activity of a polypyridyl chelating ligand: in vitro and in vivo inhibition of glioma.
David CN; Frias ES; Elix CC; McGovern KE; Walker AM; Eichler JF; Wilson EH
ASN Neuro; 2015; 7(1):. PubMed ID: 25732707
[TBL] [Abstract][Full Text] [Related]
38. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
39. Fertility and developmental toxicity assessment in rats and rabbits with LY500307, a selective estrogen receptor beta (ERβ) agonist.
Hilbish KG; Breslin WJ; Johnson JT; Sloter ED
Birth Defects Res B Dev Reprod Toxicol; 2013 Oct; 98(5):400-15. PubMed ID: 24323950
[TBL] [Abstract][Full Text] [Related]
40. The antitumor effects of Angelica sinensis on malignant brain tumors in vitro and in vivo.
Tsai NM; Lin SZ; Lee CC; Chen SP; Su HC; Chang WL; Harn HJ
Clin Cancer Res; 2005 May; 11(9):3475-84. PubMed ID: 15867250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
